Gilead Tentarix collaborates to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases using Tentarix’s proprietary TentaclesTM platform. These compounds, which are intended to improve both therapeutic benefit and safety, have the ability to conditionally target immune cells associated with disease pathways without activating other immune cells that may cause adverse outcomes.
Terms of Gilead-Tentarix Collaboration:
Tentarix will receive $66 million in upfront payments and an equity investment from Gilead across the three ventures. Furthermore, Gilead has the option to acquire up to three choice Tentarix subsidiaries housing the collaboration-developed programmes for $80 million per subsidiary.
About Tentarix Biotherapeutic’s TentaclesTM platform:
TentaclesTM are targeted, synergistic, and conditional biologics that activate a specific cell population only when all desired receptors are present.
Pipeline Molecules using TentaclesTM platform:
T cell co-agonists, regulatory T cell reprogramming, cell-specific internalizers, and T cell activators are among the classes of molecules and pathways which are in development. Tentarix is excited about the almost limitless prospects that this platform provides.
Using a combination of receptors designed for selectivity and function, Tentarix’s leading programme stimulates IL2R specifically on tumor-reactive T-cells in the tumour microenvironment. Through a synergistic secondary signal, the leading TentaclesTM are designed to stimulate and grow tumor-reactive T-cells while improving their effector capabilities and metabolic fitness.
Experts opinion on Gilead-Tentarix collaboration:
“At Gilead, a key area of our research strategy is addressing immune dysregulation in oncology and inflammatory diseases,” said Flavius Martin, M.D., Executive Vice President, Research, Gilead Sciences. “This early-stage collaboration with Tentarix will be highly synergistic to our ongoing efforts, building upon our growing strength in protein therapeutics, and may provide access to next-generation, multi-specific biologics.”
“This collaboration is part of our strategy to join forces with innovators, like Gilead, who can help us rapidly advance new medicines to the clinic,” said Paul Grayson, President and CEO of Tentarix Biotherapeutics. “Our technology has great promise and collaborating with Gilead to build out this pipeline helps broaden the development of multi-functional, antibody-based therapeutics, providing an excellent mechanism to validate our science with the ultimate goal of bringing these potential medicines to patients faster.”
